Dark

SMMT
Summit Therapeutics Inc. Common Stock
stock NASDAQ

At Close

Jun 18, 2025 3:59:48 PM EDT

20.17USD+1.612%(+0.32)2,746,663

0.00Bid 0.00Ask 0.00Spread

Pre-market

Jun 18, 2025 9:08:30 AM EDT

19.85USD0.000%(0.00)2,806

After-hours

Jun 18, 2025 4:53:30 PM EDT

20.16USD-0.050%(-0.01)228,791

OverviewOptionsHistoricalExchangesShortsNews

Jan 25, 2022

07:30AM EST Summit Therapeutics Announces Rights Offering GlobeNewswire Inc

Jan 10, 2022

08:00AM EST Summit Therapeutics Today Presents Its Company Vision at 40th GlobeNewswire Inc

Jan 5, 2022

07:30AM EST Summit Therapeutics to Present Company Vision at 40th Annual J.P. GlobeNewswire Inc

Dec 23, 2021

12:11PM EST Investigation Alert: Did You Lose Money on Your Investment? Johnson Fistel, LLP PR Newswire

Dec 20, 2021

02:49PM EST Mid-Afternoon Market Update: Dow Tumbles 500 Points; Bluerock Residential Growth Shares Spike Higher Benzinga

12:35PM EST Mid-Day Market Update: Crude Oil Drops Over 5%; Society Pass Shares Jump Benzinga

10:09AM EST Mid-Morning Market Update: Markets Open Lower; Carnival Reports Downbeat Q4 Revenue Benzinga

08:35AM EST Summit Therapeutics Announces Topline Results For Phase III Ri-CoDIFy Study For C. Difficile Infection; Says Ri-CoDIFy Did Not Meet Primary Endpoint Benzinga

08:30AM EST Summit Therapeutics Announces Topline Results for Phase III GlobeNewswire Inc

Dec 5, 2021

08:16AM EST Investigation Alert: Did You Lose Money on Your Investment? Johnson Fistel, LLP PR Newswire

Nov 15, 2021

11:12AM EST Summit Therapeutics Q3 EPS $(0.20) Up From $(0.26) YoY, Sales $1.31M Up From $181.00K YoY Benzinga

08:30AM EST Summit Therapeutics Inc. (NASDAQ: SMMT) ("Summit," "we," or the "Company") today reports its financial results and provides an update on its operational progress for the third quarter and nine months ended September 30, 2021. GlobeNewswire Inc

Nov 3, 2021

08:30AM EDT Summit Therapeutics Inc. (NASDAQ: SMMT) today announced that Dr. Urte Gayko, PhD,has been appointed to our Board of Directors, effective immediately. Dr. Gayko is currently the Senior Vice President of Drug Development & Regulatory Affairs at Nektar Therapeutics. GlobeNewswire Inc

Oct 11, 2021

03:45PM EDT Pomerantz LLP is investigating claims on behalf of investors of Summit Therapeutics Inc. (Summit or the Company) (NASDAQ: SMMT). Such investors are advised to contact Robert S. Willoughby at newaction@pomlaw.com or 888-476-6529, ext. 7980. GlobeNewswire Inc

Oct 8, 2021

08:30AM EDT Summit Therapeutics Inc. (NASDAQ: SMMT) today announced that Kenneth A. Clark, JD,has been appointed to our Board of Directors, effective immediately. Mr. Clark is currently a partner at Wilson Sonsini Goodrich & Rosati (WSGR) based out of the firms Palo Alto, CA, office. GlobeNewswire Inc

Oct 2, 2021

10:11AM EDT (SMMT) Alert: Did You Lose Money on Your Summit Therapeutics Investment? PR Newswire

Sep 30, 2021

09:03AM EDT Summit Therapeutics Presents Insights Surrounding Novel Mechanism Of Action For Investigational Drug Ridinilazole During IDWeek 2021 Benzinga

09:00AM EDT Summit Therapeutics Presents Further Breakthrough Insights GlobeNewswire Inc

08:02AM EDT Antimicrobials Working Group Highlights Member Company Participation at IDWeek PR Newswire

Sep 23, 2021

09:01PM EDT Pomerantz LLP is investigating claims on behalf of investors of Summit Therapeutics Inc. (Summit or the Company) (NASDAQ: SMMT). Such investors are advised to contact Robert S. Willoughby at newaction@pomlaw.com or 888-476-6529, ext. 7980. GlobeNewswire Inc

Sep 22, 2021

03:16PM EDT Mid-Afternoon Market Update: Dow Surges Over 400 Points; Stitch Fix Shares Spike Higher Benzinga

12:38PM EDT Mid-Day Market Update: Nasdaq Jumps 100 Points; InnovAge Shares Plummet Benzinga

11:27AM EDT Shares of Summit Therapeutics Inc. (SMMT) are slipping over 20% on Wednesday morning after the company announced that the U.S. FDA disagreed with its proposed change to the primary endpoint in Phase 3 Ri-CoDIFy studies. RTTNews

10:34AM EDT Mid-Morning Market Update: Markets Open Higher; General Mills Reports Upbeat Q1 Results Benzinga

07:45AM EDT The Daily Biotech Pulse: Pfizer-BioNTech US Vaccine Contract, Summit Slumps On Adverse Regulatory Feedback, Cerevel CFO Departs Benzinga

Sep 21, 2021

04:35PM EDT Summit Therapeutics Recent 8-K Shows Co. Received Feedback From FDA That Agency 'does not agree with the change to the primary endpoint that Summit proposed and has subsequently implemented in its ongoing Phase III Ri-CoDIFy studies...' Benzinga

Aug 11, 2021

08:11AM EDT Summit Therapeutics Q2 EPS $(0.27) Down From $(0.23) YoY, Sales $57.00K Down From $170.00K YoY Benzinga

08:03AM EDT Summit Therapeutics Announces Co. Will Combine Its Two Blinded Pivotal Phase III Clinical Trials Evaluating Ridinilazole Versus Vancomycin Into A Single Study Benzinga

08:01AM EDT Summit Therapeutics Inc. (NASDAQ: SMMT) ("Summit," "we," or the "Company") today reports its financial results and provides an update on its operational progress for the second quarter and six months ended June 30, 2021. GlobeNewswire Inc

08:00AM EDT Based on a thorough review of the design and enrollment status of two ongoing blinded Phase III Ri-CoDIFy trials, Summit Therapeutics Inc. (NASDAQ: SMMT) today announced that it will combine its two blinded pivotal Phase III clinical trials evaluating ridinilazole versus vancomycin into a single study. GlobeNewswire Inc

Aug 5, 2021

08:02AM EDT Acurx Pharmaceuticals Joins the Antimicrobials Working Group PR Newswire

Jul 12, 2021

08:31AM EDT Summit Therapeutics Presents Breakthrough Research Data from Phase GlobeNewswire Inc

08:30AM EDT Summit Therapeutics Highlights Presentation Of Data From Phase II Studies At 31st European Congress of Clinical Microbiology & Infectious Diseases Benzinga

Jul 1, 2021

08:18AM EDT Summit Therapeutics Highlights Presentation Of Research Updates At Annual European Congress of Clinical Microbiology & Infectious Diseases Conference Jul. 9-12 Benzinga

08:00AM EDT Summit Therapeutics to Present Breakthrough Research Updates at GlobeNewswire Inc

Jun 8, 2021

11:19AM EDT Crestone Joins Antimicrobials Working Group PR Newswire

07:00AM EDT Summit Therapeutics Inc. (NASDAQ: SMMT) is set to join the broad-market Russell 3000 Index at the conclusion of the 2021 Russell indexes annual reconstitution, effective after the US markets open on June 28, according to a preliminary list of additions posted by FTSE Russell. GlobeNewswire Inc

Jun 3, 2021

08:00AM EDT Summit Therapeutics Inc. (NASDAQ: SMMT) invites our shareholders and other interested parties to attend our Companys Annual Shareholders Meeting, which will be held virtually on Wednesday, June 16, 2021, at 1:00 pm Eastern Time. We look forward to your attendance at this meeting. GlobeNewswire Inc

May 18, 2021

09:02AM EDT Summit Therapeutics Unveils Preclinical Candidate For Multidrug-Resistant Infections Benzinga

07:44AM EDT The Daily Biotech Pulse: Spero Secures NIAID Funding, GlaxoSmithKline Releases COVID-19 Data, BioNTech Gets New CFO Benzinga

07:06AM EDT Summit Therapeutics Announces Selection Of Preclinical Candidate SMT026738; Also Announces Up To $4.1M Funding Award From CARB-X Benzinga

07:00AM EDT Summit Therapeutics Announces Preclinical Candidate and Associated GlobeNewswire Inc

May 17, 2021

08:10AM EDT Summit Therapeutics Q1 EPS $(0.21) Down From $(0.09) YoY, Sales $192.00K Down From $324.00K YoY Benzinga

08:00AM EDT Cambridge, MA, May 17, 2021 - Summit Therapeutics Inc. (NASDAQ: SMMT) today reports its financial results and provides an update on its operational progress for the first quarter ended March 31, 2021. GlobeNewswire Inc

May 15, 2021

01:39PM EDT Last Week's Notable Insider Buys: Activision, Avis Budget, Energy Transfer And More Benzinga

May 12, 2021

02:59PM EDT Cambridge, MA, May 12, 2021 - Summit Therapeutics Inc. (NASDAQ: SMMT) announced today the successful closing of its fully subscribed rights offering and the associated results. GlobeNewswire Inc

May 6, 2021

08:00AM EDT Cambridge, MA, May 5, 2021 - Summit Therapeutics Inc. (NASDAQ: SMMT) today announced that we have updated the scientific and related content on our corporate website with respect to our investigational drug, ridinilazole, which is currently enrolling patients in its Phase 3 clinical trials. GlobeNewswire Inc

May 5, 2021

12:47PM EDT Summit Therapeutics Rights Offering Nearing GlobeNewswire Inc

Apr 21, 2021

08:37AM EDT Summit Therapeutics Commences Previously-announced Rights Offering Of Up To 14.3 Mln Shares RTTNews

08:05AM EDT Summit Therapeutics Announces Commencement of Rights Offering GlobeNewswire Inc

Mar 26, 2021

07:02AM EDT Summit Therapeutics Reports Rights Offering For Gross Proceeds $75M Benzinga

07:00AM EDT Summit Therapeutics Announces Rights Offering GlobeNewswire Inc

Mar 17, 2021

07:11AM EDT Summit Therapeutics Q4 EPS $(0.18) Up From $(0.34) YoY Benzinga

07:08AM EDT Summit Therapeutics Q4 Loss Per Share $0.18 Vs Loss $0.34 Last Year RTTNews

07:00AM EDT Summit Therapeutics Reports Financial Results and Operational GlobeNewswire Inc

Feb 9, 2021

08:10AM EST The Daily Biotech Pulse: Dynavax Poaches GSK Vaccine Exec, KalVista Jumps On Data Readout, Corcept Issues Negative Preannouncement Benzinga

Feb 5, 2021

07:44AM EST The Daily Biotech Pulse: J&J Files For COVID-19 Vaccine Approval, Zimmer Biomet's Spin-Off, IPO Deluge Hits Street Benzinga

Jan 28, 2021

08:03AM EST The Daily Biotech Pulse: Decision Day For Amgen, Zymeworks Sinks On Data, Ortho Clinical Diagnostics IPO Benzinga

Jan 27, 2021

07:36AM EST The Daily Biotech Pulse: Sorrento, Immutep Surge On COVID-19 Study Data, T2 Biosystems Sinks On Preannouncement Benzinga

Dec 23, 2020

08:31AM EST The Daily Biotech Pulse: Supernus Issues Positive ADHD Readout, Sorrento Files For Emergency Use Authorization For Rapid COVID-19 Test, Inhibikase To Make Wall Street Debut Benzinga

Dec 18, 2020

07:48AM EST The Daily Biotech Pulse: FDA Nod For Amgen's Biosimilar, Moderna's Vaccine Vote, Mesoblast Sinks On Data Benzinga

07:45AM EST The Daily Biotech Pulse: FDA Nod For Amgen's Biosimilar, Moderna's Vaccine Approved, Mesoblast Sinks On Data Benzinga

Dec 17, 2020

08:10AM EST The Daily Biotech Pulse: MacroGenics Breast Cancer Drug Wins FDA Approval, Adcom Test Awaits Moderna, Virios To Make Wall Street Debut Benzinga

Dec 16, 2020

07:15AM EST The Daily Biotech Pulse: Novartis Gets Adcom Backing, Sio Gene Data, 2 IPOs, BioNTech Clinches China Vaccine Supply Deal Benzinga

Nov 23, 2020

07:13AM EST Summit Therapeutics Appoints Dr. Mahkam Zanganeh As Chief Operating Officer Benzinga

07:11AM EST Summit Therapeutics Appoints Mahkam Zanganeh As COO RTTNews

07:00AM EST Summit Therapeutics Appoints Dr. Mahkam GlobeNewswire Inc

Nov 18, 2020

09:37AM EST Benzinga's Top Upgrades, Downgrades For November 18, 2020 Benzinga

06:26AM EST HC Wainwright & Co. Downgrades Summit Therapeutics to Neutral Benzinga

Nov 17, 2020

08:32AM EST The Daily Biotech Pulse: Setback For Alkermes, Boston Scientific's Recall, ALX-Zymeworks Oncology Collaboration Benzinga

Nov 16, 2020

04:05PM EST Summit Therapeutics Reports Financial Results and Operational GlobeNewswire Inc

Nov 11, 2020

05:37AM EST Summit Therapeutics CEO Robert Duggan Reported Purchase of 14,071,856 Shares @ Avg Price: $3.34/Share in Form 4 Filing on Tuesday Benzinga

Nov 6, 2020

04:01PM EST Summit Announces Closing of Private Placement of $50 Million GlobeNewswire Inc

Oct 5, 2020

04:37PM EDT Summit Therapeutics S-3 Shows Registration For $200M Mixed Securities Offering Benzinga

Oct 2, 2020

06:40PM EDT Summit Announces Agreement For a Fundraising of approximately $50 GlobeNewswire Inc

Sep 29, 2020

07:07AM EDT Summit Therapeutics Q2 EPS $(0.23) Down From $(0.21) YoY, Sales $170.00K Up From $156.00K YoY Benzinga

07:00AM EDT Summit Therapeutics Reports Financial Results and Operational GlobeNewswire Inc

Sep 18, 2020

07:11AM EDT Summit Announces Effectiveness of Scheme of Arrangement and GlobeNewswire Inc

Sep 17, 2020

07:09AM EDT Summit Therapeutics Announces The The U.K. Court Approval Of Its Scheme Benzinga

07:00AM EDT Summit Therapeutics Announces U.K. Court Approval of Scheme GlobeNewswire Inc

Aug 19, 2020

04:01PM EDT Summit Announces Results of Court Meeting and General Meeting GlobeNewswire Inc

Jul 16, 2020

07:02AM EDT Summit Therapeutics To Redomicile Its Holding Company In US Benzinga

07:00AM EDT Summit Announces Intention to Redomicile its Holding Company to GlobeNewswire Inc

Jul 13, 2020

07:12AM EDT Summit Therapeutics Announces Publication of Phase 2 Clinical Analyses of Gut Microbiome Health in a Peer Reviewed Journal Benzinga

07:00AM EDT Summit Announces Publication of Phase 2 Clinical Analyses of Gut GlobeNewswire Inc